Investing.com — 2025年4月9日周三，泰瑞凡斯生物制药公司（Theravance Biopharma，NASDAQ: ...

In 2022, I wrote that Theravance had one FDA-approved product called YUPELRI (revefenacin), an inhalation solution indicated for the maintenance treatment of patients with chronic obstructive ...

This compares to the stock's 1.9% loss over the past four weeks. The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary disease, in collaboration with Viatris.